Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-01
2011-03-01
Belyavskyi, Michail A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07897729
ABSTRACT:
The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4559230 (1985-12-01), David et al.
patent: 4559231 (1985-12-01), Bjerre et al.
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 4658019 (1987-04-01), Kung et al.
patent: 5440013 (1995-08-01), Kahn
patent: 5446128 (1995-08-01), Kahn
patent: 5455165 (1995-10-01), Capon et al.
patent: 5475085 (1995-12-01), Kahn
patent: 5554372 (1996-09-01), Hunter
patent: 5618914 (1997-04-01), Kahn
patent: 5670155 (1997-09-01), Kahn
patent: 5672681 (1997-09-01), Kahn
patent: 5674976 (1997-10-01), Kahn
patent: 5679354 (1997-10-01), Morein et al.
patent: 5710245 (1998-01-01), Kahn
patent: 5714147 (1998-02-01), Capon et al.
patent: 5830731 (1998-11-01), Seed et al.
patent: 5840833 (1998-11-01), Kahn
patent: 5859184 (1999-01-01), Kahn et al.
patent: 5922845 (1999-07-01), Deo et al.
patent: 5929237 (1999-07-01), Kahn
patent: 5998166 (1999-12-01), Luo
patent: 6046310 (2000-04-01), Queen et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6262029 (2001-07-01), Press et al.
patent: 7511121 (2009-03-01), Arnason et al.
patent: 2003/0161826 (2003-08-01), Arnason et al.
patent: 0044167 (1982-01-01), None
patent: 5-503009 (1993-05-01), None
patent: 91/08298 (1991-06-01), None
patent: 92/10591 (1992-06-01), None
patent: 99/42077 (1999-08-01), None
patent: 99/58572 (1999-11-01), None
Burgess et al J Cell Biol. 111:2129-2138, 1990.
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Miller, M. L., “Treatment of systemic lupus erythematosus” Curr. Opin. Rheum., 4:693-699 (1992).
Minghetti et al., “Molecular Structure of the Human Albumin Gene Is Revealed by Nucleotide Sequence within 911-22 of Chromosome 4” J. Biol. Chem., 261:6747-6757 (1986).
Miyagi, et al., “Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis,” J. Neuroimmunol., 78:127-131 (1997).
Moingeon, et al., “CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells,” Proc Natl Acad Sci USA, 89:1492-1496 (1992).
Morgan, B. P. “The complement system: an overview” Mol Biol Methods 150, 1-13 (2000).
Morgan, et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology 86:319-324 (1995).
Morrison, S. L., et al., “Production of novel immunoglobulin molecules by gene transfection” Mt Sinai J Med 53, 175-80 (1986).
Nagler, et al., “Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo,” J. Exp. Med., 171:1527-1533 (1990).
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins” J. Mol. Biol., 48:443-453 (1970).
Nelson, H. “Targeted cellular immunotherapy with bifunctional antibodies” Cancer Cells 3, 163-72 (1991).
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, MA , pp. 433-506 (see pp. 433 and 492-495) (1994).
Nitta, T., et al., “Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells” J Neurosurg 72, 476-81 (1990).
Nolan, O., et al., “Bifunctional antibodies: concept, production and applications” Biochim Biophys Acta 1040, 1-11 (1990).
Norderhaug, L., et al., “Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells” J. Immun. Meth. 204, 77-87 (1997).
Ober et al, “Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level” The National Academy of Sciences of the United States of America, 101:11076-11081 (2004).
Ogata, M., et al., “Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol” J Biol Chem 265, 20678-85 (1990).
Ohtsuka, et al., “Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus,” J Immunol, 160:2539-2545 (1998).
Oshima et al., “Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc,” Immunology Letters, vol. 60, pp. 7-12 (1998).
Oshima et al., “Immune Recognition of Botulinum Neurotoxin Type A: Regions Recognized by T Cells and Antibodies Against The Protective Hc Fragment (Residues 855-1296) of the Toxin,” Molecular Immunology, vol. 34, pp. 1031-1040 (1997).
Paoletti and McInnes, Vaccines: From concept to clinic, CRC Press (1999).
Passwell, et al., “Increased prostaglandin production by human monocytes after membrane receptor activation,” J Immunol, 123:115-120 (1979).
Perez, P. et al., “Specific targeting of human peripheral blood t cells by heteroaggregates containing anti-t3 crosslinked to anti-target cell antibodies” Journal of Experimental Medicine, vol. 163, 166-178 (1986b).
Perez, P., et al., “Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody” Nature 316, 354-6 (1985).
Perez, P., et al., “Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody” J Immunol 137, 2069-72 (1986a).
Pfeifer, T. A. “Expression of heterologous proteins in stable insect cell culture” Curr. Opin. Biotechnol. 9, 518-21 (1998).
Pietersz, G. A., et al., “Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates” Cancer Res 48, 926-31 (1988a).
Pietersz, G. A., et al., “Specific in vitro anti-tumour activity of methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an intermediary” Immunol Cell Biol 66, 43-9 (1988b).
Plotkin and Orenstein, Vaccines, 4th Ed., Saunders press (2004).
Ptak, et al., “Heat-aggregated immunoglobulins increase in vivo immunogenicity of mouse hapten (TNP)-derivatized macrophages by upregulation of interleukin-12 secretion and expression of B7-1 and B7-2 costimulatory molecules,” Scand. J. Immunol, 51:479-484 (2000).
Radaev et al., “The Structure of Human Type III Fcg Receptor in Complex with Fc,” The Journal of Biological Chemistry, vol. 276, No. 19, pp. 16469-16477 (May 11, 2001).
Raghavan and Bjorkman, “Fc receptors and their interactions with immunoglobulins,” Ann. Rev. Cell. Dev. Biol., 12:181-220 (1996).
Regnault et al., “Fcy Receptor-mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I-restricted Antigen Presentation after Immune Complex Internalization,” J. Exp. Med., vol. 189, pp. 371-380 (Jan. 1999).
Remington's Pharmaceutical Sciences, 14th Ed., Mack Printing Company (1970).
Remington's Pharmaceutical Sciences, 18th Ed., Mack
Arnason Barry G. W.
Jensen Mark A.
White David M.
Belyavskyi Michail A
Guttman Harry J.
Iterative Therapeutics, Inc.
Stipkala LLC
LandOfFree
Polymeric immunoglobulin fusion proteins that target low... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymeric immunoglobulin fusion proteins that target low..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymeric immunoglobulin fusion proteins that target low... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683687